MTOR and Alzheimer disease: We and others have also shown that chronic mTOR attenuation with rapamycin can prevent and reverse cognitive and cerebrovascular deficits in several independent mouse models of AD (Lin et al., 2017, 2013;Van Skike et al., 2018) and vascular cognitive impairment (Jahrling et al., 2018), leading to improved cerebrovascular function and preserved cognitive outcomes in these models of age‐related disease.